MedTrace Logo

Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver

NCT06030232 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 202

Last updated 2024-04-24

No results posted yet for this study

Summary

Radioembolization is an established treatment option for patients with unresectable primary and secondary liver tumors. Microspheres containing 90Y are injected intraarterially to deliver a high radiation dose to the tumors. Despite of our knowledge on the effectiveness of 90Y glass microspheres in the treatment of HCC, literature data on the treatment of metastatic colorectal cancer (mCRC) patients with 90Y glass microspheres is limited. In the recent EANM guideline variable healthy liver doses are recommended for patients with mCRC with an effective tumor dose recommendation based on a study with limited number of patients.

Primary objectives; Investigate effective tumor dose and safe healthy liver dose in radioembolization for colorectal cancer liver metastasis using multicompartment dosimetry Secondary objectives; Investigate dose-response and dose-toxicity relationships, time to progress, concordance between pretreatment and posttreatment dose calculations.

Conditions

  • Transarterial Radioembolization

Interventions

DEVICE

Therasphere

Transarterial radioembolization

Sponsors & Collaborators

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • Ankara University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-15
Primary Completion
2024-03-15
Completion
2024-04-15
FDA Device
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06030232 on ClinicalTrials.gov